Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cridanimod - Pharmsynthez/Xenetic Biosciences

Drug Profile

Cridanimod - Pharmsynthez/Xenetic Biosciences

Alternative Names: Sodium cridanimod; Virexxa; XBIO-101

Latest Information Update: 05 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmsynthez
  • Developer AS Kevelt; Pharmsynthez; Xenetic Biosciences
  • Class Acetic acids; Acridines; Antineoplastics; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Immunomodulators; Interferon stimulants; Progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Endometrial cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Endometrial cancer
  • Preclinical Breast cancer

Most Recent Events

  • 31 Mar 2019 Xenetic Biosciences closes patient enrolment in a phase II trial in Endometrial cancer in the US (NCT03077698)
  • 06 Mar 2019 Cridanimod is available for licensing as of 04 Mar 2019. https://www.xeneticbio.com/product-pipeline/xbio-101
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top